who are ineligible for autologous hematopoietic stem cell transplantation (HSCT), according to a news release from AstraZeneca. Importantly, Calquence is now the first and only Bruton tyrosine kinase ...
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
Acalabrutinib, made by the drug company AstraZeneca and marketed under the brand name Calquence, works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which helps cancerous B cells ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca Q4 revenue rose 18% to $14.89 ... Tagrisso sales were up 20% to $1.70 billion (21% at CER), Calquence sales increased 20% to $808 million, Lynparza sales increased 46% (+47%) to ...
Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...
AstraZeneca’s other drugs, Fasenra, Calquence, Breztri and newer products, asthma drug Tezspire, breast cancer drug Truqap and lupus drug Saphnelo (anifrolumab) are likely to have contributed to ...
WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...
Wide-moat AstraZeneca’s fourth-quarter results were ... especially oncology drugs such as Imfinzi, Tagrisso, Calquence, Truqap, and Enhertu. The company gave a brief update on ongoing ...